AbbVie: a pharma giant navigating its defining transition (ABBV)
From The Gemini Brief - Investment Deep Dives · 00:52:03
Show by Lukasz Tomicki and LRT Capital Management LLC
Slide Deck AbbVie has executed what may be the most successful franchise replacement in pharmaceutical history. The company’s combined Skyrizi and Rinvoq revenues reached $25.9 billion in 2025 — surpassing Humira’s all-time peak of $21.2 billion — while Humira itself declined to $4.5 billion from that peak. Total revenue hit a record $61.2 billion in […]
More episodes of The Gemini Brief - Investment Deep Dives
More episodes
- Autodesk (ADSK): a powerful franchise priced for mediocrity
- American Financial Group (AFG): a specialty P&C compounder facing its first real test
- Analog Devices (ADI): a high-quality compounder navigating cyclical recovery and geopolitical crosscurrents
- ADP,, Inc. (ADP): A fortress business at an inflection point
- Matson Inc: a protected franchise with an identity crisis (MATX)
- Trinity Industries: a leasing company in manufacturer’s clothing (TRN)
- M/I Homes: a competent operator without a moat (MHO)
- Investment Research Report: Adecoagro SA (AGRO)
- Investment Research Report: Central Puerto S.A. (CEPU)
- Pampa Energia (PAM): Argentina’s integrated energy bet on structural reform
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.